Biotech Values

[stuck_holder]

wall, that is not accurate.

$53.2M leftover from the previous shelf must be common, but the remaing $147 could be any combination of preferred, debt, warrants including commmon.

http://google.brand.edgar-online.com/fetchFilingFrameset.aspx?FilingID=5040858&Type=HTML

fwiw, i expect they will issue common for most if not all of the $147M since i expect a chunk of that will go to a partner in the form of an equity investment, plus the company has forecasted that they will be cash flow negative for the next two years (additional Provenge trials, Neuvenge, trp-8, re-starting R&D, etc.), making interest or preferred dividend payments on issuance of debt/preferred equity less attractive, plus i suspect they are thinking that dilution via common will be less of an issue as the price increases.

the one fly in the ointment is the artifical depression of the market price due to naked short selling which directly impacts the equity interest of every existing long...that is something the company, in particular Schiffman should be addressing whether with the SEC, and/or via alternative means, such as issuing a property dividend of stock warrants to shareholders of record or similar action.

fwiw, i have given up reading most of the IV MB posts, in part because the one aspect where the leverage of apparently 11M DNDN shares held by IV MB readers could, imo, be effectively applied has been essentially ignored by that MB, in favor of pursuing hussain or some other negative panel members. if you really want to screw the shorts, that is the best and perhaps only way to actually do so.